Search - tctmd.com

Displaying 1 - 20 of 3006

Sort: Relevancy | Date

Patients With Obesity Get Biggest Benefit from Evolocumab: FOURIER

News Daily News

Patients With Obesity Get Biggest Benefit from Evolocumab: FOURIER

Michael O'Riordan

December 12, 2025

WHO Endorses Treating Obesity in Adults With GLP-1s

News Daily News

WHO Endorses Treating Obesity in Adults With GLP-1s

December 01, 2025

Online Calculator Allows Young Adults to See How Their 30-Year CV Risk Compares to Peers’

News Daily News

Online Calculator Allows Young Adults to See How Their 30-Year CV Risk Compares to Peers’

Yael L. Maxwell

November 19, 2025

Sham-Controlled Trial, and More, Bolster Pulsed-Field Ablation for AF

News Conference News AHA 2025

Sham-Controlled Trial, and More, Bolster Pulsed-Field Ablation for AF

November 17, 2025

Olezarsen Cuts Triglycerides, Pancreatitis Risk in Severe Hypertriglyceridemia

News Conference News AHA 2025

Olezarsen Cuts Triglycerides, Pancreatitis Risk in Severe Hypertriglyceridemia

Michael O'Riordan

November 14, 2025

Prasugrel May Be Better Than Ticagrelor After PCI for Diabetes Patients With MVD

News Conference News AHA 2025

Prasugrel May Be Better Than Ticagrelor After PCI for Diabetes Patients With MVD

November 13, 2025

DARE-AF Dapagliflozin Fails to Reduce AF Burden After Catheter Ablation

News Conference News AHA 2025

DARE-AF Dapagliflozin Fails to Reduce AF Burden After Catheter Ablation

November 12, 2025

Fish Oil Halves CV Risk in Patients on Dialysis: PISCES

News Daily News

Fish Oil Halves CV Risk in Patients on Dialysis: PISCES

Yael L. Maxwell

November 10, 2025

Evolocumab Cuts MACE Risk in Patients Without Prior MI, Stroke: VESALIUS-CV

News Conference News AHA 2025

Evolocumab Cuts MACE Risk in Patients Without Prior MI, Stroke: VESALIUS-CV

Michael O'Riordan

November 08, 2025

CRISPR-Cas9 Gene-Editing Therapy Shows Early Promise for Dyslipidemia

News Conference News AHA 2025

CRISPR-Cas9 Gene-Editing Therapy Shows Early Promise for Dyslipidemia

November 08, 2025

What’s Going to Be Hot at AHA 2025?

News Opinion Editor's Corner AHA 2025

What’s Going to Be Hot at AHA 2025?

Michael O'Riordan

November 05, 2025

PREVENT-TAHA8: Post-MI Intracoronary Stem Cells May Lower HF Risk After STEMI

News Daily News

PREVENT-TAHA8: Post-MI Intracoronary Stem Cells May Lower HF Risk After STEMI

November 04, 2025

Ultrathin-Strut DES Performs Well vs Xience in Diabetic Patients: TUXEDO-2

News Conference News TCT 2025

Ultrathin-Strut DES Performs Well vs Xience in Diabetic Patients: TUXEDO-2

November 03, 2025

STRIVE: Low-Dose Alteplase Ineffective in STEMI Patients With Large Thrombus

News Conference News TCT 2025

STRIVE: Low-Dose Alteplase Ineffective in STEMI Patients With Large Thrombus

Michael O'Riordan

October 28, 2025

ENCIRCLE: Good Results With Sapien M3 Transseptal TMVR

News Conference News TCT 2025

ENCIRCLE: Good Results With Sapien M3 Transseptal TMVR

October 27, 2025

PREVUE-VALVE Charts the Prevalence of Valve Disease in the United States

News Conference News TCT 2025

PREVUE-VALVE Charts the Prevalence of Valve Disease in the United States

October 27, 2025

Mechanical Thrombectomy Outshines Anticoagulation Alone in STORM-PE

News Conference News TCT 2025

Mechanical Thrombectomy Outshines Anticoagulation Alone in STORM-PE

October 26, 2025

Biomarkers Added to a Polygenic Risk Score Equals Better CAD Prediction

News Daily News

Biomarkers Added to a Polygenic Risk Score Equals Better CAD Prediction

Yael L. Maxwell

October 23, 2025

Imperfect Evidence: How Strong Is the Case for Transcatheter Tricuspid Valve Interventions?

News Features

Imperfect Evidence: How Strong Is the Case for Transcatheter Tricuspid Valve Interventions?

October 22, 2025

Cardiac Transplant in Midst of ‘Revolution,’ but Public Trust Is Fragile

News Features

Cardiac Transplant in Midst of ‘Revolution,’ but Public Trust Is Fragile

Michael O'Riordan

October 17, 2025

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.